As with many situations we face, there is likely no definite "one" answer to this question. That being said, I tend to like gemcitabine + platinum (usually carboplatin) since it is generally well tolerated and, for those who feel strongly about retaining hair, usually does not lead to hair loss. In ...

My preference is carboplatin + gemcitabine. The phase III study of gem/cis vs pem/cis demonstrated superiority of gemcitabine in squamous NSCLC (Scagliotti et al., PMID 18506025), and while the addition of necitumumab did improve survival, it comes at notable toxicity and financial cost that, in my ...

It's not a drug per se, but for patients with oligometastatic disease to the lungs (1-5 metastases), there is good overall survival data for the addition of SBRT (Stereotactic Body Radiation Therapy). It more than doubles the odds of 5 year overall survival.In the SABR-COMET trial 5-year update in t...